Monopar Therapeutics Inc. announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging clinical trial of MNPR-101-Zr. This novel radiopharmaceutical imaging agent combines MNPR-101, Monopar?s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the radioisotope zirconium-89. Monopar?s Phase 1 clinical trial, led by internationally recognized nuclear medicine physician Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre, aims to assess the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancers.

This is the first human study to evaluate a radiolabeled monoclonal antibody targeting uPAR.